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Available online 27 June 2016Multiple sclerosis (MS) is a neurodegenerative disease of the central nervous system (CNS). Minimally invasive
biomarkers of MS are required for disease diagnosis and treatment. Differentially methylated circulating-free
DNA (cfDNA) is a useful biomarker for disease diagnosis and prognosis, and may offer to be a viable approach
for understanding MS. Here, methylation-speciﬁc primers and quantitative real-time PCR were used to study
methylation patterns of the myelin oligodendrocyte glycoprotein (MOG) gene, which is expressed primarily in
myelin-producing oligodendrocytes (ODCs). MOG-DNA was demethylated in O4+ ODCs in mice and in DNA
from human oligodendrocyte precursor cells (OPCs) when compared with other cell types. In the cuprizone-
fed mousemodel of demyelination, ODC derived demethylatedMOG cfDNAwas increased in serum andwas as-
sociated with tissue-wide demyelination, demonstrating the utility of demethylatedMOG cfDNA as a biomarker
of ODC death. Collected sera from patients with active (symptomatic) relapsing-remitting MS (RRMS) demon-
strated a higher signature of demethylated MOG cfDNA when compared with patients with inactive disease
and healthy controls. Taken together, these results offer a minimally invasive approach to measuring ODC
death in the blood of MS patients that may be used to monitor disease progression.39, Mineola,
. This is an o© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Multiple sclerosis (MS) is a neurodegenerative disease characterized
by demyelination of axons in the central nervous system (CNS). The
cells that produce myelin in the CNS, oligodendrocytes (ODCs) (Bunge
et al., 1962; Bunge, 1968), die from an autoimmune response that
results in demyelinated lesions in the brain and spinal cord
(Noseworthy et al., 2000; Olsen and Akirav, 2015). Axonal demyelin-
ation reduces the signal strength of nerve impulses (Waxman, 1977;
Felts et al., 1997) and may leave the axon exposed to degeneration
(Ferguson et al., 1997). Demyelinated lesions can be visualized by mag-
netic resonance imaging (MRI); however, this procedure is costly and
cannot detect diffused or mild myelin degeneration or measure the
active loss of ODCs. Although new innovations in MS therapy are cur-
rently being explored (Olsen and Akirav, 2015), there are currently no
clinically approved molecular biomarkers of ODC death in MS. This
unmet need impairsMS diagnosis, prognosis, and assessment of clinical
intervention.NY 11501, USA.
pen access article underDNA methylation is a mechanism involved in the control of tissue-
speciﬁc gene expression (Jones, 2012). DNA hypermethylation of CpG
dinucleotides acts as an inhibitor of transcription while hypomethyla-
tion is associated with increased gene expression. Differences in DNA
methylation patterns between different cell types can be used to deter-
mine the origin of the DNA. Accordingly, methylated circulating-free
DNA (cfDNA) is used as a biomarker of tumor progression (Nawroz et
al., 1996; Chen et al., 1996; Crowley et al., 2013). Our group has success-
fully adapted this approach for the detection of β-cell loss in patients
with autoimmune type 1 diabetes (Akirav et al., 2011), where differen-
tially methylated β-cell derived insulin cfDNAwas used to detect β-cell
loss. A recent report by Lehmann-Werman et al. showed the utility of
using cfDNA to detect cell loss in MS, by measuring demethylated
cfDNA of MBP and WM1 genes, showing an increase in the levels of
demethylated DNA in patients with MS (Lehmann-Werman et al.,
2016).
In contrast to MBP, which is found in both ODCs and Schwann cells,
and WM1, whose tissue expression patterns are largely unknown, my-
elin oligodendrocyte glycoprotein (MOG) is a CNS-speciﬁc protein
expressed solely by ODCs as an integral part of the myelin sheath
(Linnington et al., 1984; Lebar et al., 1986; Gardinier et al., 1992; Johns
and Bernard, 1999). The speciﬁcity of MOG in ODCs suggests that thethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Primer sequences and PCR protocols for mouse MOG analysis.
PCR type Primer designation Primer sequence 5′→ 3′ Product length PCR protocol
First-step PCR Forward GAGTGATAGGATTAGGGTATTTTATT 169 bp 50 cycles, annealing temperature 57 °C
Reverse TCTACATCTTAATCCTTACCATTTC
Methylation-speciﬁc nested qPCR Common forward GAGTGATAGGATTAGGGTATTTTATT 87 bp 40 cycles, annealing temperature 64 °C
Hypermeth-speciﬁc reverse TAACGTTCTTCCCAAAAAATATACG
Hypometh-speciﬁc reverse TAACATTCTTCCCAAAAAATATACA
Native sequence ﬁrst-step PCR Forward GAGTGATAGGACCAGGGTATCCCATC 169 bp Cycles no. variable, annealing temperature 57 °C
Reverse CTGCATCTTGGTCCTTGCCATTTC
228 J.A. Olsen et al. / EBioMedicine 10 (2016) 227–235MOG gene may present with unique methylation patterns in ODCs,
which can be used to detect ODC-derived DNA in the blood and assess
disease activity in patients with MS. Here we identify demethylated
CpG dinucleotides in ODCs from mouse and human origin that are ab-
sent in other cell types in the brain and periphery. Methylation-speciﬁc
primers for demethylated MOG-DNA were able to detect ODC-speciﬁc
DNA in puriﬁed primarymouse ODCs and primary human oligodendro-
cyte precursor cells (OPCs). When used to detect ODCMOG-DNA in the
sera, these primers showed an increase in ODC-derived cfDNA in mice
treated with cuprizone. Testing of human primers successfully detected
ODC MOG cfDNA in sera of patients with relapsing-remitting MS
(RRMS) and showed a correlation with disease activity.2. Methods
2.1. Mice
C57BL/6 female mice purchased from Jackson Laboratory (Bar
Harbor, ME) were started on a diet of rodent chowwith 0.2% cuprizone
(ResearchDiets Inc., NewBrunswick, NJ) at 8weeks of age (Day 0).Mice
were divided into 2 groups of 6 (total n= 12) with blood sampling by
cheek pouch bleed on Days 0, 7, 21, 35, and 49 for group 1 and Days 0,
14, 28, and 42 for group 2. On Day 56 blood was obtained from all
mice via heart puncture. Brain tissueswere collected for histological anal-
ysis of myelination. All animal care was approved by the Winthrop-
University Hospital Institutional Animal Care and Use Committee.2.2. Cell and Cell Lines
SW10 immortalized neuronal murine Schwann cells were pur-
chased from American Type Culture Collection (Manassas, VA) and cul-
tured using the provided protocols. Cells were pelleted for DNA
extraction. Human OPC genomic DNA extracts (ScienCell Research Lab-
oratories, Carlsbad, CA) were used as a positive control sample for
demethylated MOG-DNA. This genomic DNA sample was obtained
from ScienCell Research Laboratories from early passage human OPCs
using the AllPrep DNA/RNA Mini Kit (Qiagen N.V., Valencia, CA).2.3. Mouse Tissues
Mouse liver, kidney, and brain tissue were obtained from a C57BL/6
mouse (Jackson Laboratory, Bar Harbor, ME) and homogenized for DNA
extraction.Table 2
Primer sequences and PCR protocols for human MOG analysis.
PCR type Primer designation Primer sequence 5′
First-step PCR Forward GGGTAGTTTAGAGT
Reverse TAAAAATAAACCAC
Methylation-speciﬁc nested qPCR Common forward GGGTAGTTTAGAGT
Hypermeth-speciﬁc reverse TAACGTTTTTCTCAA
Hypometh-speciﬁc reverse TAACATTCTTCCCAA2.4. Enrichment of O4+ Cells
O4+ cells were puriﬁed from the brains of ﬁve C57BL/6 mice
(Jackson Laboratory, BarHarbor,ME) and treatedwith theNeural Disso-
ciation Kit (P) and Anti-O4 MicroBeads, followed by magnetic puriﬁca-
tion on the autoMACS Pro Separator (Miltenyi Biotec Inc., Auburn, CA).
2.5. FACS Staining
Evaluation of O4+ fraction purity was performed by ﬂuorescence-
activated cell sorting (FACS) analysis. Magnetically puriﬁed ODCs
werewashed twice and suspended in FACS buffer containing anti-O4 la-
beled antibody or isotype control and analyzed using anAccuri FACS an-
alyzer (BD Biosciences, San Diego, CA). FACS data was analyzed using
FlowJo software (FlowJo, Ashland, OR).
2.6. Plasmid Injections
Four C57BL/6 mice (Jackson Laboratory, Bar Harbor, ME) were each
administered an intravenous injection of TOPO plasmid containing the
demethylated mouse MOG sequence. Five minutes following injection,
blood was obtained by heart puncture.
2.7. Histology
Brain tissues from cuprizone or sham treated mice were collected
immediately following euthanasia, embedded in O.C.T. compound
(Fisher, Waltham, MA) and snap frozen in liquid nitrogen. Tissues
were sectioned at 7 μm thickness and mounted on poly-D-lysine coated
slides, followed by formalin ﬁxation. Myelin staining was done using a
NovaUltra Luxol Fast Blue Staining Kit according to the manufacturer's
instructions (IHCworld, Woodstock, MD). Stained slides were imaged
using a bright ﬁeld on a Nikon Eclipse Ti confocal microscope (Nikon,
Melville, NY).
2.8. Human Subject Samples
Serum samples were obtained from BioServe Biotechnologies, Ltd.
(Beltsville,MD). Sampleswere designated as “Active” if having a relapse
at the time of sampling, “Inactive” if in remission at the time of sam-
pling, or “Healthy Control” based on donor information. Disease activity
was determined by specialized neurologists at the time of sampling and
included a combination of disease activity by patient admission, EDSS
scoring andMRI imaginingwhere applicable. In some cases, MS activity→ 3′ Product length PCR protocol
GATAGGATTAAGATAT 152 bp 50 cycles, annealing temperature 57 °C
CCTAAAAAAAA
GATAGGATTAAGATAT 97 bp 40 cycles, annealing temperature 64 °C
AAAATATACG
AAAATATACA
Table 3
Demographic and disease history for RRMS and control subjects.
Parameters Groups
Ctrl RRMS
Inactive Active
N (all females) 20 20 20
Ethnicity (W/AA) 20/0 19/1 20/0
Age (years) 41.3 ± 1.5 40.20 ± 1.75 41.3 ± 1.5
Age at dx (years) – 32.5 ± 2.1 32.8 ± 1.6
Disease duration (years) – 7.7 ± 1.3 8.6 ± 1.1
aDuration from last epi (years) – 1.5 ± 0.5 –
bTime between epi (years) – 1.9 ± 0.4 1.6 ± 0.6
a 18/20 patients reporting.
b 29/40 patients reporting.
229J.A. Olsen et al. / EBioMedicine 10 (2016) 227–235was determined primarily by physician assessment and patient reports.
Demographic information, disease activity, disease duration, duration
from the last episode, and time between episodes are summarized in
Table 3.2.9. DNA Puriﬁcation and Bisulﬁte Conversion
DNA extraction from homogenized tissue, sera, and cell pellets was
performed using theDNEasy Blood and TissueKit (QiagenN.V., Valencia,
CA). DNA concentration was measured with the Quant-iT PicoGreen
dsDNA Assay Kit (Life Technologies, Carlsbad, CA). DNA extracts were
bisulﬁte treated with the EZ DNA Methylation-Direct Kit (Zymo
Research, Irvine, CA).Fig. 1. Illustrative representation of biomarker assay used to detect oligodendrocyte death in m
circulation. Blood is collected from the patient, DNA is puriﬁed, and bisulﬁte converted. Pos
primers and loaded onto an agarose gel. First-step PCR product is extracted and used as a temp2.10. Bisulﬁte Sequence Prediction and Primer Design
Prediction of methylated CpG in speciﬁc regions of the human and
mouse MOG gene was done using the MethPrimer program (Li and
Dahiya, 2002). Sequence output was used to design methylation insen-
sitive and sensitive primers.
2.11. First-step PCR and Gel Extraction
A ﬁrst-step PCR using non-methylation-speciﬁc primers and EpiTaq
HS Kit (Clonetech Laboratories Inc., Mountain View, CA) was run to in-
crease template availability. First-step products were run on a 2% aga-
rose gel and isolated using the QIAquick Gel Extraction Kit (Qiagen
N.V., Valencia, CA). No template controls in the ﬁrst-step reaction
were free of products. Mouse and human primer sequences are de-
scribed in Tables 1 and 2, respectively.
2.12. Cloning of MOG-DNA
Bisulﬁte treated ﬁrst-step PCR products puriﬁed from agarose gel
were used as templates for a TOPO TA cloning reaction using the pCR
2.1TOPO vector (Invitrogen, Carlsbad, CA). ODC+ and liver ﬁrst-step
MOG products were used as the mouse demethylated and methylated
inserts, respectively. Human demethylated and methylated DNA
(Zymo Research, Irvine, CA) ﬁrst-step MOG products were used for
the human demethylated and methylated inserts, respectively. NEB 5-
alpha competent Escherichia coli (New England Biolabs, Ipswich, MA)
were used for transformation with the TOPO MOG products and incu-
bated at 37 °C overnight on ImMedia Kan Agar plates (Invitrogen, Carls-
bad, CA). Individual colonies were added to a culture of LB broth/ultiple sclerosis. Myelin-producing oligodendrocytes die and release genomic DNA into
t-bisulﬁte conversion, samples are run on ﬁrst-step PCR using methylation-unspeciﬁc
late for qPCR utilizing methylation-speciﬁc primers.
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QIAprep Spin Miniprep Kit (Qiagen N.V., Valencia, CA) was used to pu-
rify the TOPO plasmid from the cultures.
2.13. McrBC Restriction Enzyme Reaction
Puriﬁed DNA from human liver, brain, and spinal cord fraction was
treated with the McrBC methylation-speciﬁc restriction enzyme (New
England Biolabs Inc., Ipswich, MA). After treatment, 70 ng of treated
and untreated liver, spinal cord or brain DNA, as well as a TOPO plasmid
containing the appropriate native MOG insert, were run on PCR using
native MOG primers. Samples were run on PCR and were removed at
cycle 32 or 35. PCR products were run on a 2% agarose gel and imaged
using a 4000R Image Station (Eastman Kodak Co., Rochester, NY).
2.14. Sequencing of MOG-DNA
MOG ﬁrst-step PCR gel extracts and MOG Plasmid DNA were se-
quenced at the Keck Biotechnology Research Laboratory (New Haven,
CT).
2.15. Analysis of MOG Methylation in Primary Murine O4+ and O4−
Fractions
First-step PCR product of bisulﬁte treated DNA frommouse O4+ and
O4− fractions, SW10 Schwann cells, and liver were cloned using pCR
2.1TOPO vector (Invitrogen, Carlsbad, CA). NEB5-alpha competent E.
coli (New England Biolabs, Ipswich, MA) were used for the transforma-
tion reaction and individual colonies were treated with the ZymoFig. 2.Murine brain and spinal cord show differential methylation in the MOG gene, due to the
tissues. Arrows point toward CpG sites where cytosines (C) are preserved inmethylated sample
leading to a mixed population of C′s and T's (Brain, Spinal Cord). B. Methylation-sensitive DNA
McrBC enzyme. Digested DNA was subjected to semi-quantitative PCR (cycles 32 and 35) a
McrBC enzyme. Pos—positive control using cloned native MOG DNA. NTC—no template con
magnetic beads. FACS analysis showed N92.6 ± 3.9% enrichment of O4+ cells among four ind
is differentially methylated in the MOG gene compared to DNA from O4− cells, the SW10 Sch
each sample, 10 clones from each are shown (○ represent demethylated cytosines; ●, me
methylation-speciﬁc murine primers incorporate the CpG site at bp +2752.Zyppy-96 Plasmid Miniprep (Zymo Research, Irvine, CA) prior to se-
quencing. Puriﬁed clones were sequenced by the Keck Biotechnology
Research Laboratory (New Haven, CT).
2.16. Methylation-sensitive Real Time PCR
Gel-extracted ﬁrst-step PCR products served as a template for quan-
titative real-time PCR (qPCR) using methylation-sensitive primers
(Sigma-Aldrich Corp., St. Louis, MO) designed for bisulﬁte treated
MOG-DNA. All reactions were run using LightCycler 480 SYBR Green I
Master (Roche Diagnostics GmbH, Germany) PCR mix on a CFX96
Real-Time System (Bio-Rad Laboratories Inc., Hercules, CA). Relative
quantiﬁcation of demethylated DNA was calculated using the demeth-
ylation index (DMI)= 2(methylated cycle number) − (demethylated cycle number).
2.17. Statistical Analysis
Results are reported asmean±SEM. Statistical signiﬁcance (p b 0.05)
of differences between means was calculated by one-way ANOVA and
Tukey's post hoc test using Prism 5 (GraphPad software). In some
cases, t-test was used to compare two individual treatment groups.
ROC analysis of Active vs. Inactive RRMS was performed with Prism 5.
3. Results
3.1. MOG Gene DNA Shows Unique Methylation in the CNS
The concept of using DNAmethylation as a biomarker of ODC loss is
described in Fig. 1. Previous reports show the expression of MOG in their O4+ cell population. A. Sanger sequencing results of bisulﬁte treated DNA from murine
s (Liver, Kidney), or converted to thymines (T) in samples containing demethylated CpGs,
digestion was performed on the magnetically spinal cord of liver derived-DNA using the
nd run on agarose gel. UnTx—untreated DNA receiving all reaction components except
trol. C and D. O4+ and O4− cells were separated from four separate murine brains by
ependent preparations when compared to O4− fractions. E. DNA from murine O4+ cells
wann cell line, and liver. Sequence analysis was performed on ﬁrst-step PCR product of
thylated cytosines). Locations in relation to the MOG transcription start site are listed,
231J.A. Olsen et al. / EBioMedicine 10 (2016) 227–235brain, however, the role of epigenetics in controlling MOG expression
remains largely unknown. To examine whether the MOG gene is
demethylated in the CNS, DNA frommurine liver, kidney, brain and spi-
nal cord was isolated and subjected to bisulﬁte sequencing. Bisulﬁte
treatment of DNA leads to the conversion of cytosine (C) to thymine
(T) in demethylated (DeMeth) CpGs (C → T), while methylated
(Meth) mCpGs remain intact (C→ C). Sequence analysis of DNA from
murine brain and spinal cord tissues revealed an increase in C→ T con-
version when compared with DNA from liver and kidney, demonstrat-
ing the presence of DeMeth CpGs in CNS tissue (Fig. 2A). Analysis of
MOG DNA methylation in native DNA by the methylation sensitive
restriction enzyme, McrBC, conﬁrmed the presence of demethylated
MOG DNA in spinal cord DNA when compared with liver DNA
(Fig. 2B). Similar results were obtained using brain DNA (data not
shown). ODCs are considered the only source of MOG protein in
the brain. Therefore, in order to conﬁrm that MOG-DNA was indeed
demethylated in ODCs and not in other cell types, brains from nor-
mal mice were digested and cells labeled with anti-O4 magnetic
beads, followed by magnetic separation. FACS analysis of enriched
O4+ and O4− primary cell fractions were 92.6 ± 3.9% pure in four in-
dependent O4+ preparations when compared with the O4− fraction
(Fig. 2C and D). Puriﬁed O4+ and O4− cells were lysed and genomic
DNA puriﬁed and bisulﬁte converted. Analysis of MOG-DNA methyl-
ation state in both fractions revealed unique methylation patterns in
O4+ cells but not in O4− cells (Fig. 2E). Schwann cells mediate the
myelination of peripheral nerves and are MOG negative. Analysis of
the DNA methylation patterns in DNA from murine Schwann cell
line and liver (negative control) showed a complete methylation of
four CpG dinucleotides in MOG gene, demonstrating the fact thatFig. 3.Methylation-speciﬁc primers display high speciﬁcity and sensitivity and can detect deme
region utilized for mousemethylation-speciﬁc qPCR analysis; cytosine at bp+2752 fromMOG
primers tested using plasmids containing methylated and demethylated murine MOG-DNA ins
primers were used in qPCRwith bisulﬁte treated DNA frommurine liver, kidney, brain, and spin
Cord p b 0.001, Kidney vs. Brain/Spinal Cord p b 0.001. D. Methylation-speciﬁc primers were us
analyses used to compute DMI averages; ANOVA p= 0.0008, O4+ vs. O4− p b 0.01, O4+ vs. SWMOG demethylation is unique to ODCs (Fig. 2E and Supplemental
Fig. 1). Taken together these data show demethylation patterns in
the MOG-DNA from primary ODCs when compared with other CNS
cell types, Schwann cells, and peripheral tissues, suggesting that
these differences in methylation can be used as a biomarker of ODC
loss.3.2. Methylation Speciﬁc Primers Detect DeMeth MOG-DNA in Murine CNS
Tissues and Puriﬁed ODCs
The identiﬁcation of demethylated CpG dinucleotides in primary
ODCs and CNS tissues prompted us to design methylation-speciﬁc
primers capable of discerning betweenMeth and DeMeth CpGs in posi-
tion +2752 of the murine MOG gene (Table 1 and Fig. 3A). Plasmids
containing the Meth and DeMeth DNA sequence of the MOG gene
were used as controls for primer sensitivity and speciﬁcity. Serial dilu-
tion of plasmids over a 6 log dilution range showed the ability of
DeMeth speciﬁc primers to detect DeMeth DNA even when diluted at
1:1000 in Meth-DNA (Fig. 3B, R2 = 0.987, p b 0.0001). When tested
on bisulﬁte-treated DNA from murine tissues, methylation-speciﬁc
primers showed a strong signal in both brain and spinal cord tissues
when compared with liver and kidney DNA (Fig. 3C. ANOVA
p b 0.0001. Liver vs. Brain or SC p b 0.001. Kidney vs. Brain or SC
p b 0.001). Comparison of puriﬁed O4+ ODCs with both O4− and
SCW10 showed similar results, with O4+ cells producing a statistically
higher signal when compared with either cell (Fig. 3D. ANOVA p =
0.0008, O4+ vs. O4− p b 0.01. O4+ vs. Schwann cells p b 0.01). Taken to-
gether, these results show the ability of methylation-speciﬁc primers tothylatedMOG-DNA inmurine brain, spinal cord, and O4+ cells. A. A depiction ofMOG gene
transcription start site incorporated into reverse primer sequence. B. Methylation-speciﬁc
erts over a wide range of serial dilutions (R2 = 0.987, p b 0.0001). C. Methylation-speciﬁc
al cord. Three independent analyses used to compute DMI averages; Liver vs. Brain/Spinal
ed in qPCR with murine O4+ cells, O4− cells, and SW10 Schwann cells. Three independent
10 Schwann cells p b 0.01.
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be used to detect ODC-derived cfDNA in the serum.
3.3. Circulating Free DeMeth MOG-DNA Is Detected in Sera of Mice with
Widespread Demyelination
To examine whether DeMeth-speciﬁc primers can be used to detect
DeMeth MOG in the blood, healthy C57BL/6 mice were injected with a
plasmid containing an insert of DeMeth DNA of the MOG gene. Blood
was collected 5 min post injection by heart puncture and circulating
free serum DNA was puriﬁed. The level of DeMeth DNA in serum DNA
was expressed as DMI. Extracted DNA from plasmid treated mice
showed a 24-fold increase in DeMeth MOG-DNA when compared
with untreated controls (Fig. 4A, Tx vs. Ctrl p b 0.012), demonstrating
the ability of DeMeth-speciﬁc primers to detect DeMeth MOG-DNA in
the serum. Next, we used the cuprizone mouse model of MS. In this
model, ODC injury is induced by treatment with the copper chelating
agent, cuprizone. Cheek pouch bleeding was performed on a weekly
basis following cuprizone administration to measure the levels of
ODC-derived DeMeth MOG cfDNA in the blood. Baseline DMI (Fig. 4B,
solid line) was established using normal untreated mice (n= 9). Aver-
age MOG DMIs (n = 12, 6 mice per time point) reached their highest
peak over baseline at Day 14, with increased DMI levels continuing
through Days 21 and 28 before returning to baseline levels on Day 35
(Fig. 4B). Luxol fast-blue staining of brain tissue sections showed a
gross demyelination in cuprizone-treated mice but not untreated
mice, conﬁrming the dramatic effect on myelin in the brain (Fig. 4C).
These data demonstrate the ability of methylation-speciﬁc primers to
detect DeMeth MOG-DNA in the blood of mice treated with the ODC-
speciﬁc toxin, supporting the use of DeMeth MOG-DNA as a biomarker
of ODC cell loss in MS.Fig. 4.Methylation-speciﬁc primers can detect DeMeth MOG-DNA in the serum of plasmid inj
neural tissue. A. Bisulﬁte-treated DNA from the serum of mice injected with DeMeth MOG pl
Ctrl p b 0.012. B. Bisulﬁte-treated DNA from the serum of cuprizone-fed mice (n = 12) was
elevated over baseline until Day 35. C. Brain sections from cuprizone-fed and control mice stai3.4. Human MOG-DNA is Demethylated in the Brain and Can Be Detected
byMethylation-speciﬁc Primers in Primary Oligodendrocyte Precursor Cells
The detection of DeMeth MOG-DNA in mouse CNS and primary
ODCs suggested that MOG may be demethylated in CNS and ODCs of
human origin. The demethylated CpG pairs detected in the mouse
assay are evolutionarily conserved between both human and mouse
(Fig. 5A). Analysis of bisulﬁte-treated DNA from human brain revealed
the presence of demethylated CpG dinucleotides while these CpG
pairs were fully methylated in DNA from human liver (Fig. 5B). This
analysis was supported by cloning of puriﬁed DNA from both brain
and liver which showed the presence of unique demethylation patterns
on single DNA strands in the brain. These patterns were absent when
liver DNA was cloned and sequenced Fig. 5C). The difference in MOG-
DNA methylation between the brain and liver allowed for the design
of methylation-speciﬁc primers for the human MOG gene (Table 2).
Similar to the mouse assay, cloned plasmids containing the Meth and
DeMeth DNA sequences of the human MOG gene were synthesized,
and mixed at varied ratios over 6 logarithmic concentrations followed
by analysis using methylation-speciﬁc qPCR. A positive correlation
was observed between DMI level and MOG DeMeth plasmid (Fig. 5D,
R2=0.992, p b 0.0001). Next, we comparedDMI values of DNA fromol-
igodendrocyte precursor cells (OPCs) and liver tissues. Methylation-
speciﬁc primers yielded DMI values of OPC DNA that were 136-fold
higher than those of liver DNA, showing a sensitivity and speciﬁcity of
the methylation speciﬁc primers (Fig. 5E). These differences were fur-
ther validated by comparing DMI values of plasmids containing Meth
or DeMeth MOG-DNA (data not shown). Taken together, these results
show the presence of differentially methylated CpG dinucleotides in
the human brain and OPCs. Methylation-speciﬁc primers can success-
fully detect these DeMeth CpGs in DNA puriﬁed from the OPC,ected mice and in cuprizone-treated mice which can be correlated with demyelination in
asmid and non-injected mice was run on qPCR with methylation-speciﬁc primers; Tx vs.
run on qPCR with methylation-speciﬁc primers; MOG DMIs peak at Day 14 and remain
ned for myelin using Luxol fast-blue; arrows indicate the region of native myelination.
233J.A. Olsen et al. / EBioMedicine 10 (2016) 227–235suggesting that this approach may be used to detect ODC death in pa-
tients with MS.
3.5. Circulating Free DeMeth MOG-DNA Levels Are Increased in Patients
with Active Relapsing-remitting MS
The ability of methylation-speciﬁc primers to successfully detect
DeMeth MOG-DNA from OPCs suggests that this approach may be
used to detect ODC-derived MOG cfDNA in patients with relapsing-
remitting MS (RRMS). Serum samples from RRMS patients with active
or inactive disease at the time of blood sampling were compared to
sera of age and gender-matched healthy individuals for DMI values.
MS patients with active and inactive disease showed similar age
medians and disease duration (Fig. 6A: Age—Inactive = 40.2 ± 1.75,
Active = 41.30 ± 1.5; Fig. 6B: Disease duration—Inactive = 7.7 ± 1.3,
Active=8.6± 1.1). DNAwas puriﬁed from 300 μl of sera, bisulﬁte-con-
verted, ampliﬁed by a ﬁrst-step PCR reaction, and analyzed by qPCR
using methylation-speciﬁc primers. DMI values were calculated based
on three independent PCR reactions. DMI values of patients with active
disease were 3.6 folds higher than inactive disease showing statistical
signiﬁcance (Fig. 6C, DMI—Healthy controls = 9.23 × 10−2 ±
2.16 × 10−2, Inactive MS = 4.89 × 10−2 ± 2.49 × 10−2, Active =
18.36 × 10−2 ± 5.18 × 10−2. ANOVA p b 0.029; Inactive vs. Active
p b 0.05). ROC analysis of samples showed an AUC of 0.7475 with 95%
conﬁdence interval of 0.59–0.9. This analysis reached statistical signiﬁ-
cance (Fig. 6D, p b 0.007). Taken together, our data show, for the ﬁrst
time, the utility of MOG cfDNA to detect active MS in patients with
RRMS.Fig. 5.Methylation-speciﬁc primers display high speciﬁcity and sensitivity and can detect demet
humanmethylation-speciﬁc qPCR analysis; cytosines at bps+2410 and+2430 fromMOG tran
of bisulﬁte treated DNA from human tissues. Arrows point toward CpG siteswhere cytosines (C
containing demethylated CpGs, leading to a mixed population of C′s and T's (Brain). Red arrow
methylated in the MOG gene compared to DNA from the liver. Sequence analysis was perfor
DNA are shown (○ represent demethylated cytosines; ●, methylated cytosines). Locations
primers incorporate the CpG sites at bp +2410 and +2430. D. Methylation-speciﬁc primers t
over a wide range of serial dilutions (R2 = 0.992, p b 0.0001). E. Methylation-speciﬁc prime
precursor cells. Three independent analyses used to compute DMI averages.4. Discussion
Differentially methylated cfDNA can be used as a biomarker of can-
cer and autoimmune diabetes. Here we report the presence of differen-
tially methylated CpG dinucleotides in the coding region of the MOG
gene in ODCs. These DeMeth CpGs are detected bymethylation-speciﬁc
primers and measure the presence of ODC-derived MOG cfDNA in the
blood of mice with widespread demyelination. Moreover, methyla-
tion-speciﬁc primers for human MOG-DNA can detect increased ODC
loss in the sera of patients with active RRMSwhen compared with inac-
tive disease and healthy controls. Our results describe a new assay for
measuring differentially methylated MOG cfDNA as a minimally inva-
sive biomarker of ODC loss in RRMS. A biomarker capable of measuring
ODC loss may advance our ability to better diagnose MS progression in
conjunction with current imaging techniques, allow for better disease
prognosis andmodeling of ODC cell loss, and for measuring clinical efﬁ-
cacy of novel therapeutic agents.
MOG expression is found predominantly in ODCs (Coffey and
McDermott, 1997; Solly et al., 1996). Recent reports suggest that meth-
ylation may play an active role in the transcription of MOG as the ex-
pression of methyl-CpG binding protein 2 can bind to Meth CpGs and
inhibit the expression of several myelin components, including MOG
(Solly et al., 1996). Despite these ﬁndings, little is known about the
state of MOG-DNA methylation and the role methylation plays in gene
regulation. The data presented above show the presence of several
demethylated CpGs in DNA from primary mouse ODCs and primary
human OPCs when compared with other tissues. These demethylated
dinucleotides were absent in other cell types and tissues and arehylatedMOG-DNA inhuman brain and liver. A. A depiction ofMOGgene regionutilized for
scription start site incorporated into reverse primer sequence. B. Sanger sequencing results
) are preserved in themethylated sample (Liver), or converted to thymines (T) in a sample
s indicate CpGs incorporated into reverse primers. C. DNA from the brain is differentially
med on ﬁrst-step PCR product of each sample, 13 clones of liver and 23 clones of brain
in relation to the MOG transcription start site are listed; methylation-speciﬁc human
ested using plasmids containing methylated and demethylated human MOG-DNA inserts
rs were used in qPCR with bisulﬁte treated DNA from human liver and oligodendrocyte
234 J.A. Olsen et al. / EBioMedicine 10 (2016) 227–235evolutionarily conserved in theMOGcoding region.While our data does
not address the role of methylation in the regulation of MOG gene ex-
pression, our ﬁndings provide a strong support for it in both murine
and human cells. The presence of DeMeth CpG pairs in MOG-DNA
from ODCs provided an opportunity to design methylation-speciﬁc
primers for the detection of ODC-derived DNA. This approach was pre-
viously used to detect the loss of insulin producing β-cells in patients
and animal models of type 1 diabetes (Akirav et al., 2011; Olsen et al.,
2016) and for identifying cell loss in MS (Lehmann-Werman et al.,
2016). Methylation speciﬁc primers showed a high degree of speciﬁcity
for Meth or DeMeth MOG-DNAwhen tested on both artiﬁcially synthe-
sized DNA and DNA from ODC and brain origin, suggesting that these
primers may detect as little as 1 copy of DeMeth DNA in 1000 copies
of Meth MOG-DNA.
The fact that these primerswere able to detect DeMethMOG-DNA in
mice injected with artiﬁcial DNA conﬁrmed the ability of the assay to
detect ODC-like DNA in vivo. To further test the ability of the primers
to detect ODC cell loss, we used the cuprizone model of ODC-toxicity
and widespread demyelination in mice. In previous reports, ODC gene
expression in the brain, used as an indicator of ODC function and
mass, was reduced early during treatment, with the reemergence of
MAG-expressing cells in the brains of cuprizone-treated mice from
week 6 onwards post treatment (Lindner et al., 2008; Praet et al.,
2014). Additional studies report complete remyelination in the
cuprizone mice upon removal of the cuprizone diet. The remyelination
was complemented with the detection of several myelin proteins,
excluding MOG, whose expression was delayed for several weeks
(Lindner et al., 2008; Praet et al., 2014). Indeed, Methylation-speciﬁc
primers detected ODC-cell loss as early as 3weeks post cuprizone treat-
ment, with the highest increase detected at Day 14 post treatment.
Moreover, our results showed relatively low levels of ODC-derived
DeMeth MOG-DNA in the blood of mice from week 5 until week 8
post-treatment, corresponding to previous reports showing theFig. 6.Methylation-speciﬁc primers can detect elevated levels of demethylated MOG cfDNA in
active and inactive disease groups. B. Duration of disease of relapsing-remitting multiple sclero
with bisulﬁte treated DNA extracted from sera fromHealthy Controls, Inactive and Active RRMS
an AUC of 0.7475 with 95% conﬁdence interval of 0.59–0.9. This analysis reached statistical sigreemergence of ODCs in the brain. Our overall ﬁndings suggest that
ODC loss can be detected during the acute or toxic phase of cuprizone
administration while in later time points the ablation of ODCs resulted
in reduced ODC-derived DNA in the blood.
The detection of ODC-derived DeMeth MOG-DNA in the cuprizone
mouse model lead us to examine the methylation state of the MOG
gene in human DNA. Analysis of an evolutionarily conserved region of
MOG-DNA in human brains and liver showed an identical demethyla-
tion pattern in CpG dinucleotides also present in mouse MOG. The fact
that sequencing analysis of brainDNA revealed only a partial conversion
of C → T suggests that non-ODC cells contribute to the Meth form of
MOG-DNA while ODCs are the sole source of DeMeth MOG-DNA as
seen in the O4+ and O4− cell fractions in the mouse. Methylation-
speciﬁc primers designed to distinguish between theMeth and DeMeth
form of CpGs +2410 and +2430 showed a high degree of speciﬁcity
and sensitivity similar to that of the mouse assay, and were able to de-
tect DeMethMOG in brain DNA at DMI levels nearly 10,000 folds higher
than those observed in the liver. When tested, these primers showed a
high DMI signal in OPCs when compared with liver, showing the ability
of the assay to detect ODC-like DNA.
The high degree of sensitivity and speciﬁcity of the humanmethyla-
tion-speciﬁc primers allowed us to analyze blood samples from 40 pa-
tients with RRMS, with active (n = 20) or inactive (n = 20) disease.
Healthy controls (n=20)were also used to establish the baseline back-
ground DMI levels of normal subjects. Disease activity in RRMS patients
was determined by clinical episodes and, in some cases, by the forma-
tion of new brain lesions in the CNS. While both RRMS patients with in-
active and active disease were similar in age, gender, and duration of
disease, patients with active RRMS had signiﬁcant elevation in DMI
values. ROC analysis of active and inactive RRMS revealed average
AUC and preliminary cutoff values of speciﬁcity and sensitivity for
assay performance. Additional studies consisting of larger patient co-
horts would be needed to validate these values and allow for their usepatients with RRMS. A. Age at diagnosis of relapsing-remitting multiple sclerosis for both
sis for both active and inactive groups. C. Methylation-speciﬁc primers were used in qPCR
patients; ANOVA p b 0.029, Inactive vs. Active p b 0.05. D. ROC analysis of samples showed
niﬁcance (p b 0.007).
235J.A. Olsen et al. / EBioMedicine 10 (2016) 227–235in the clinic. To our knowledge, this is the ﬁrst report demonstrating the
utility of differentiallymethylatedODC-derived cfDNAas a biomarker of
cell loss in RRMS where DMI levels reﬂect disease activity.
This report describes thedifferentialmethylation of theMOGgene in
ODCs and brain tissues of both mouse and human origin. The unique
DeMeth patterns in ODCs provide a new biomarker for the detection
of ODC-cell loss in MS. Currently, diagnosis of MS is based on several
criteria (Polman et al., 2011), including identiﬁcation of lesions by MRI
and positive identiﬁcation of biomarkers in cerebral spinal ﬂuid (CSF).
MS is a ﬁnancially burdening disease (Adelman et al., 2013; Kobelt et
al., 2006), making MRIs cost-prohibitive for many underinsured pa-
tients. Despite the ongoing identiﬁcation of useful biomarkers in CSF
testing (Teunissen et al., 2015; Fitzner et al., 2015), lumbar punctures
are an invasive procedure which prevents collecting samples from
healthy individuals. The collection of cfDNA is a cost effective,minimally
invasive procedure that can be implemented for diagnosis, prognosis,
and monitoring of treatment efﬁcacy. The ability to measure ODC loss
may prove beneﬁcial not only to MS but also to other disease afﬂicting
ODC survival such as progressive multifocal leukoencephalopathy
(PML).
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.06.031.
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